Why the study?
Do p53 mutations or p16/p14ARF homozygous deletions predict poor chemoresponse and overall survival in patients with Ewing sarcoma?
Population
60 patients with Ewing sarcoma confirmed to contain EWS-FLI1 or EWS-ERG fusions.
Comparison
Presence of p53 mutation or p16/p14ARF… vs Absence of p53 mutation or p16/p14ARF homozygous…
Design
Cohort
Authors
Loading...
p53/p16 alterations mark highest-risk Ewing sarcoma; hypothesis-generating and requires prospective validation before guiding therapy.
Do p53 mutations or p16/p14ARF homozygous deletions predict poor chemoresponse and overall survival in patients with Ewing sarcoma?
Alterations in p53 or p16/p14ARF define a highly aggressive subset of Ewing sarcoma associated with poor chemoresponse and overall survival.
Huang et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: